AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test
The first patent application recently allowed relates to COVID and other neutralizing antibody (Nab) testing and treatment.
- The first patent application recently allowed relates to COVID and other neutralizing antibody (Nab) testing and treatment.
- The allowance confirms that AXIM was a pioneer in developing a rapid point of care Nab test and its novelty.
- Additionally, the company was notified by the USPTO of a second patent allowance for systems and methods for rapid diagnostic for various cancers.
- 1 Utility Patent Application
The invention relates to a Rapid Point of Care test for Human Monomeric Lacritin.